MRSN logo

Mersana Therapeutics (MRSN) Cash From Operations

Annual CFO

-$168.88 M
-$119.52 M-242.12%

December 31, 2023


Summary


Performance

MRSN Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherMRSNcash flowmetrics:

Quarterly CFO

-$8.58 M
+$13.28 M+60.75%

September 30, 2024


Summary


Performance

MRSN Quarterly CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherMRSNcash flowmetrics:

TTM CFO

-$95.05 M
+$37.50 M+28.29%

September 30, 2024


Summary


Performance

MRSN TTM CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherMRSNcash flowmetrics:

Cash From Operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

MRSN Cash From Operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-242.1%+81.4%+49.5%
3 y3 years-126.1%+81.4%+49.5%
5 y5 years-205.9%+81.4%+49.5%

MRSN Cash From Operations Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-242.1%at low-115.7%+86.1%-134.5%+49.5%
5 y5-year-242.1%at low-115.7%+86.1%-134.5%+49.5%
alltimeall time-634.6%at low-115.7%+86.1%-396.4%+49.5%

Mersana Therapeutics Cash From Operations History

DateAnnualQuarterlyTTM
Sep 2024
-
-$8.58 M(-60.8%)
-$95.05 M(-28.3%)
Jun 2024
-
-$21.86 M(-33.1%)
-$132.56 M(-23.2%)
Mar 2024
-
-$32.66 M(+2.2%)
-$172.53 M(+2.2%)
Dec 2023
-$168.88 M(+242.1%)
-$31.96 M(-30.6%)
-$168.88 M(-10.2%)
Sep 2023
-
-$46.08 M(-25.5%)
-$188.15 M(+115.1%)
Jun 2023
-
-$61.83 M(+113.2%)
-$87.47 M(+24.2%)
Mar 2023
-
-$29.00 M(-43.4%)
-$70.41 M(+42.6%)
Dec 2022
-$49.36 M(-64.7%)
-$51.23 M(-193.8%)
-$49.36 M(+21.8%)
Sep 2022
-
$54.60 M(-221.9%)
-$40.53 M(-69.1%)
Jun 2022
-
-$44.78 M(+462.9%)
-$131.23 M(+8.5%)
Mar 2022
-
-$7.96 M(-81.2%)
-$120.92 M(-13.6%)
Dec 2021
-$139.99 M(+87.4%)
-$42.40 M(+17.5%)
-$139.99 M(+21.8%)
Sep 2021
-
-$36.10 M(+4.7%)
-$114.91 M(+16.1%)
Jun 2021
-
-$34.47 M(+27.6%)
-$99.00 M(+23.0%)
Mar 2021
-
-$27.02 M(+56.0%)
-$80.47 M(+7.7%)
Dec 2020
-$74.70 M
-$17.32 M(-14.2%)
-$74.70 M(+6.8%)
Sep 2020
-
-$20.20 M(+26.7%)
-$69.95 M(+5.9%)
Jun 2020
-
-$15.94 M(-25.0%)
-$66.04 M(+2.7%)
DateAnnualQuarterlyTTM
Mar 2020
-
-$21.25 M(+68.9%)
-$64.30 M(-5.1%)
Dec 2019
-$67.74 M(+22.7%)
-$12.58 M(-22.8%)
-$67.74 M(-4.7%)
Sep 2019
-
-$16.28 M(+14.7%)
-$71.07 M(+8.9%)
Jun 2019
-
-$14.20 M(-42.5%)
-$65.26 M(+4.4%)
Mar 2019
-
-$24.69 M(+55.2%)
-$62.51 M(+13.2%)
Dec 2018
-$55.22 M(+29.4%)
-$15.90 M(+51.8%)
-$55.22 M(+9.8%)
Sep 2018
-
-$10.47 M(-8.5%)
-$50.31 M(-1.2%)
Jun 2018
-
-$11.45 M(-34.2%)
-$50.92 M(+3.6%)
Mar 2018
-
-$17.39 M(+58.1%)
-$49.16 M(+15.2%)
Dec 2017
-$42.68 M(-235.1%)
-$11.00 M(-0.8%)
-$42.68 M(+130.6%)
Sep 2017
-
-$11.08 M(+14.4%)
-$18.51 M(+51.7%)
Jun 2017
-
-$9.69 M(-11.2%)
-$12.20 M(+7.1%)
Mar 2017
-
-$10.91 M(-182.8%)
-$11.39 M(-136.1%)
Dec 2016
$31.59 M(-427.8%)
$13.18 M(-375.9%)
$31.59 M(+71.6%)
Sep 2016
-
-$4.78 M(-46.2%)
$18.41 M(-20.6%)
Jun 2016
-
-$8.88 M(-127.7%)
$23.19 M(-27.7%)
Mar 2016
-
$32.07 M
$32.07 M
Dec 2015
-$9.64 M
-
-

FAQ

  • What is Mersana Therapeutics annual cash flow from operations?
  • What is the all time high annual CFO for Mersana Therapeutics?
  • What is Mersana Therapeutics annual CFO year-on-year change?
  • What is Mersana Therapeutics quarterly cash flow from operations?
  • What is the all time high quarterly CFO for Mersana Therapeutics?
  • What is Mersana Therapeutics quarterly CFO year-on-year change?
  • What is Mersana Therapeutics TTM cash flow from operations?
  • What is the all time high TTM CFO for Mersana Therapeutics?
  • What is Mersana Therapeutics TTM CFO year-on-year change?

What is Mersana Therapeutics annual cash flow from operations?

The current annual CFO of MRSN is -$168.88 M

What is the all time high annual CFO for Mersana Therapeutics?

Mersana Therapeutics all-time high annual cash flow from operations is $31.59 M

What is Mersana Therapeutics annual CFO year-on-year change?

Over the past year, MRSN annual cash flow from operations has changed by -$119.52 M (-242.12%)

What is Mersana Therapeutics quarterly cash flow from operations?

The current quarterly CFO of MRSN is -$8.58 M

What is the all time high quarterly CFO for Mersana Therapeutics?

Mersana Therapeutics all-time high quarterly cash flow from operations is $54.60 M

What is Mersana Therapeutics quarterly CFO year-on-year change?

Over the past year, MRSN quarterly cash flow from operations has changed by +$37.50 M (+81.39%)

What is Mersana Therapeutics TTM cash flow from operations?

The current TTM CFO of MRSN is -$95.05 M

What is the all time high TTM CFO for Mersana Therapeutics?

Mersana Therapeutics all-time high TTM cash flow from operations is $32.07 M

What is Mersana Therapeutics TTM CFO year-on-year change?

Over the past year, MRSN TTM cash flow from operations has changed by +$93.10 M (+49.48%)